# Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression

Source: https://onco.cc/trials/nct04180371/  
OnCo record `nct04180371` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Nivolumab in ovarian cancer and non-small-cell lung cancer, run by BicycleTx Limited, active and no longer recruiting.

## Summary

Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression is a phase 1/2 interventional study registered as NCT04180371 by BicycleTx Limited, with 288 participants planned, started 2019-11-07 and due to reach its primary completion in 2026-07-31. Interventions recorded: BT5528, Nivolumab. Conditions listed: Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer, Ovarian Cancer, Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04180371
- Phase: 1/2
- Setting: Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT5528 in Patients With Advanced Malignancies Associated With EphA2 Expression
- Sponsor: BicycleTx Limited
- Enrolled: 288

## Sources

- ClinicalTrials.gov NCT04180371: https://clinicaltrials.gov/study/NCT04180371

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Nivolumab](https://onco.cc/drugs/nivolumab/)
- companies: [Bicycle Therapeutics](https://onco.cc/companies/bicycle-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct04180371.json